H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

Equities research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Eton ...

Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the ...

Adjusted EBITDA was $2.6 million in the quarter. The company said it mined 813 bitcoin in the period and ended the quarter ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.